期刊
MOLECULAR AND CELLULAR ENDOCRINOLOGY
卷 361, 期 1-2, 页码 1-11出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2012.03.026
关键词
STAT5; Non-alcoholic fatty liver disease; Glucose metabolism; Glucocorticoids; Growth hormone
资金
- Austrian Science Funds (FWF) [SFB F28, F2807-B20]
- Vienna Science and Technology Fund (WWTF) [LS07-058]
- Boehringer Stiftung
- Deutsche Forschungsgemeinschaft [TU220/3, TU220/6]
- European Union FP7-BrainAge
- Austrian Science Fund (FWF) [F 2807] Funding Source: researchfish
Growth hormone (GH) and glucocorticoids (GCs) are involved in the control of processes that are essential for the maintenance of vital body functions including energy supply and growth control. GH and GCs have been well characterized to regulate systemic energy homeostasis, particular during certain conditions of physical stress. However, dysfunctional signaling in both pathways is linked to various metabolic disorders associated with aberrant carbohydrate and lipid metabolism. In liver, GH-dependent activation of the transcription factor signal transducer and activator of transcription (STAT) 5 controls a variety of physiologic functions within hepatocytes. Similarly, GCs, through activation of the glucocorticoid receptor (GR), influence many important liver functions such as gluconeogenesis. Studies in hepatic Stat5 or GR knockout mice have revealed that they similarly control liver function on their target gene level and indeed, the GR functions often as a cofactor of STAT5 for CH-induced genes. Gene sets, which require physical STAT5-GR interaction, include those controlling body growth and maturation. More recently, it has become evident that impairment of GH-STAT5 signaling in different experimental models correlates with metabolic liver disease, ranging from hepatic steatosis to hepatocellular carcinoma (HCC). While GH-activated STAT5 has a protective role in chronic liver disease, experimental disruption of GC-GR signaling rather seems to ameliorate metabolic disorders under metabolic challenge. In this review, we focus on the current knowledge about hepatic CH-STAT5 and GC-GR signaling in body growth, metabolism, and protection from fatty liver disease and HCC development. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据